Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.64 |
| ▸ | GRM8 | O00222 | 1/20 | 0.64 |
| ▸ | GRM6 | O15303 | 1/20 | 0.64 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.64 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.64 |
| ▸ | GSR | P00390 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.64 |
| ▸ | GRM5 | P41594 | 1/20 | 0.64 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.64 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.64 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.64 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.64 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.64 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.64 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.64 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.64 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.64 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.64 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30973852 | 1.00 | FOLH1 (0.64) | FOLH1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL30973850 | 1.00 | FOLH1 (0.64) | FOLH1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL1769459 | 1.00 | FOLH1 (0.64) | FOLH1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL12210209 | 1.00 | FOLH1 (0.64) | FOLH1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL9223132 | 1.00 | FOLH1 (0.64) | FOLH1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL9225173 | 1.00 | FOLH1 (0.64) | FOLH1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL6853383 | 1.00 | FOLH1 (0.64) | FOLH1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL9688034 | 1.00 | FOLH1 (0.64) | FOLH1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL22750154 | 1.00 | FOLH1 (0.64) | FOLH1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL30973851 | 1.00 | FOLH1 (0.64) | FOLH1GRM8GRM6GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 288 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015393-A1 | NOVEL NMU RECEPTOR 2 AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2026-01-15 | — | — | US | claimed |
| US-20250382344-A1 | Soluble GLP1/GIP/NPY2 Receptor Triple Agonists | BOEHRINGER INGELHEIM INT GMH (DE) | 2025-12-18 | — | — | US | claimed |
| US-20250326814-A1 | MODIFIED OXYNTOMODULIN AND METHODS OF USE THEREOF | OPKO BIOLOGICS LTD. (IL) | 2025-10-23 | — | — | US | claimed |
| CN-118451091-A | Cleavable radioligands for targeting cell surface receptors and uses thereof | 辐联科技香港有限公司 | 2024-08-06 | — | — | CN | claimed |
| US-12050228-B2 | Automated sample quality assessment | METABOLON, INC. (US) | 2024-07-30 | — | — | US | claimed |
| CN-117677302-A | Peptide compounds for flavor modulation | CJ第一制糖株式会社 | 2024-03-08 | — | — | CN | claimed |
| US-20230410977-A1 | METHODS AND MATERIALS FOR ASSESSING RADIATION EXPOSURE | NUTECH VENTURES | 2023-12-21 | — | — | US | claimed |
| US-20230103631-A1 | PEPTIDES AS SELECTIVE GIP RECEPTOR AGONISTS | SANOFI (FR) | 2023-04-06 | — | — | US | claimed |
| CN-115884982-A | Peptides as selective GIP receptor agonists | 赛诺菲 | 2023-03-31 | — | — | CN | claimed |
| EP-4110800-A1 | PEPTIDES AS SELECTIVE GIP RECEPTOR AGONISTS | SANOFI (FR) | 2023-01-04 | — | — | EP | claimed |
| EP-1002535-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2000-05-24 | — | — | EP | claimed |
| WO-2000024395-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | IKONOMIDOU HRISSANTHI (DE) | 2000-05-04 | — | — | WO | claimed |
| EP-0559175-B1 | gamma-Polyglutamate hydrolase and process for producing same | MEIJI SEIKA KAISHA (JP) | 1999-07-14 | — | — | EP | claimed |
| US-5757408-A | PRINTING IMAGE ON SUBSTRATE COATED WITH AMINO-ACID DERIVATIVE ADDITIVE; QUICK DRYING OF INK, OPTICAL DENSITY, NONCURLING | XEROX CORPORATION (US) | 1998-05-26 | — | — | US | claimed |
| US-5683793-A | Ink jet transparencies | XEROX CORPORATION (US) | 1997-11-04 | — | — | US | claimed |
| US-5444061-A | Antitumor agents | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1995-08-22 | — | — | US | claimed |
| EP-0667246-A1 | Recording sheets containing amino acids, hydroxy acids, and polycarboxyl compounds | XEROX CORPORATION (US) | 1995-08-16 | — | — | EP | claimed |
| US-5356805-A | Gamma-polyglutamate hydrolase | MEIJI SEIKA KAISHA, LTD. (JP) | 1994-10-18 | — | — | US | claimed |
| EP-0559175-A2 | gamma-Polyglutamate hydrolase and process for producing same | MEIJI SEIKA KAISHA LTD. (JP) | 1993-09-08 | — | — | EP | claimed |
| EP-0266905-A1 | Reagents for assay of gamma-glutamyl-transpeptidase | UNITIKA LTD. (JP) | 1988-05-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015393-A1 | NOVEL NMU RECEPTOR 2 AGONISTS | NMUR2, NMUR1, GPR18 | FOLH1 547/4885GRM8 151/4885GRM6 248/4885 |
| US-20250326814-A1 | MODIFIED OXYNTOMODULIN AND METHODS OF USE THEREOF | OGFRL1, OXGR1, THOP1 | FOLH1 1679/4885GRM8 690/4885GRM6 430/4885 |
| US-20250382344-A1 | Soluble GLP1/GIP/NPY2 Receptor Triple Agonists | GLP1R, GIPR, NPY1R | FOLH1 479/4885GRM8 962/4885GRM6 1031/4885 |
| US-20230103631-A1 | PEPTIDES AS SELECTIVE GIP RECEPTOR AGONISTS | GIPR, GLP1R, GPR119 | FOLH1 740/4885GRM8 275/4885GRM6 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.